Madrigal Pharmaceuticals Stock Forum

$SPDR S&P Biotech ETF(XBI.US)$
$Merck & Co(MRK.US)$ x $Immunovant(IMVT.US)$
$Eli Lilly and Co(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$Gilead Sciences(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$Bristol-Myers Squibb(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals(MDGL.US)$$Viking Therapeutics(VKTX.US)$$Akero Therapeutics(AKRO.US)$$89bio(ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics(VKTX.US)$$Eli Lilly and Co(LLY.US)$$Novo-Nordisk A/S(NVO.US)$

Morning Movers
Gapping up
$Madrigal Pharmaceuticals(MDGL.US)$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US)$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US)$ stock f...

$Madrigal Pharmaceuticals(MDGL.US)$ REZDIFFRA as first & only US approved therapy for nonalcoholic steatohepatitis 🎉
ℹ️ REZDIFFRA (Resmetirom)
⇒ THR-β agonist
⇒ once-daily oral therapy #NASH 💊
⇒ Ph3 MAESTRO-NASH trial
⇒ NDA
⇒ PDUFA: 3/14/24
⇒ Approved under accelerated approval 👏

$Madrigal Pharmaceuticals(MDGL.US)$ This market is so made up lmao. The price dropped 10% today and the FDA news was leaked before close, but if you check the options, they’re already priced in even with the massive intraday drop. Just shows how fake everything is and how many others are aware of information far before others.

Last week’s PDUFAs:
$BeiGene(BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ®  + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ® 
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...